Preventive Service Usage and New Chronic Disease Diagnoses: Using PCORnet Data to Identify Emerging Trends, United States, 2018–2022

Background Data modernization efforts to strengthen surveillance capacity could help assess trends in use of preventive services and diagnoses of new chronic disease during the COVID-19 pandemic, which broadly disrupted health care access. Methods This cross-sectional study examined electronic health record data from US adults aged 21 to 79 years in a large national research network (PCORnet), to describe use of 8 preventive health services (N = 30,783,825 patients) and new diagnoses of 9 chronic diseases (N = 31,588,222 patients) during 2018 through 2022. Joinpoint regression assessed significant trends, and health debt was calculated comparing 2020 through 2022 volume to prepandemic (2018 and 2019) levels. Results From 2018 to 2022, use of some preventive services increased (hemoglobin A1c and lung computed tomography, both P < .05), others remained consistent (lipid testing, wellness visits, mammograms, Papanicolaou tests or human papillomavirus tests, stool-based screening), and colonoscopies or sigmoidoscopies declined (P < .01). Annual new chronic disease diagnoses were mostly stable (6% hypertension; 4% to 5% cholesterol; 4% diabetes; 1% colonic adenoma; 0.1% colorectal cancer; among women, 0.5% breast cancer), although some declined (lung cancer, cervical intraepithelial neoplasia or carcinoma in situ, cervical cancer, all P < .05). The pandemic resulted in health debt, because use of most preventive services and new diagnoses of chronic disease were less than expected during 2020; these partially rebounded in subsequent years. Colorectal screening and colonic adenoma detection by age group aligned with screening recommendation age changes during this period. Conclusion Among over 30 million patients receiving care during 2018 through 2022, use of preventive services and new diagnoses of chronic disease declined in 2020 and then rebounded, with some remaining health debt. These data highlight opportunities to augment traditional surveillance with EHR-based data.

[1]  J. Shapiro,et al.  Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021 , 2023, Preventing chronic disease.

[2]  A. Jemal,et al.  Annual Report to the Nation on the Status of Cancer, part 2: Early assessment of the COVID‐19 pandemic’s impact on cancer diagnosis , 2023, Cancer.

[3]  Meghan C Martinez,et al.  Factors associated with adherence to provider referrals for lung cancer screening with low dose computed tomography before and during COVID-19 pandemic , 2023, BMC Cancer.

[4]  A. Jemal,et al.  Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment. , 2023, The Lancet. Oncology.

[5]  S. Vernon,et al.  Perceived barriers to cervical cancer screening and motivators for at-home human papillomavirus self-sampling during the COVID-19 pandemic: Results from a telephone survey , 2023, eLife.

[6]  S. J. Henley,et al.  Trends in breast cancer mortality by race/ethnicity, age, and US census region, United States─1999‐2020 , 2022, Cancer.

[7]  Janet S. Wright,et al.  Impacts of the COVID-19 Pandemic on Nationwide Chronic Disease Prevention and Health Promotion Activities , 2022, American Journal of Preventive Medicine.

[8]  H. Assi,et al.  COVID-19 and lung cancer: update on the latest screening, diagnosis, management and challenges , 2022, The Journal of international medical research.

[9]  H. Stolp,et al.  Commitment to Hypertension Control During the COVID-19 Pandemic: Million Hearts Initiative Exemplars , 2022, Preventing chronic disease.

[10]  P. Gosse,et al.  Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension , 2022, Blood pressure.

[11]  Hilary K. Wall,et al.  How Do We Jump-Start Self-measured Blood Pressure Monitoring in the United States? Addressing Barriers Beyond the Published Literature. , 2022, American journal of hypertension.

[12]  D. Sheffield,et al.  Systematic Review of Self-Monitoring of Blood Glucose in Patients With Type 2 Diabetes , 2021, Nursing research.

[13]  L. Erhunmwunsee,et al.  Racial and socioeconomic disparities in lung cancer screening in the United States: A systematic review , 2021, CA: a cancer journal for clinicians.

[14]  J. Eberth,et al.  Disparities in Meeting USPSTF Breast, Cervical, and Colorectal Cancer Screening Guidelines Among Women in the United States , 2021, Preventing chronic disease.

[15]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. , 2021, Circulation.

[16]  Shimul A. Shah,et al.  Impact of the COVID-19 Pandemic on Lung Cancer Screening Program and Subsequent Lung Cancer , 2020, Journal of the American College of Surgeons.

[17]  A. Mengozzi,et al.  Short-term impact of COVID-19 lockdown on metabolic control of patients with well-controlled type 2 diabetes: a single-centre observational study , 2020, Acta Diabetologica.

[18]  D. Harper,et al.  The future of cancer screening after COVID‐19 may be at home , 2020, Cancer.

[19]  D. Patt,et al.  Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors , 2020, JCO clinical cancer informatics.

[20]  W. Polonsky,et al.  The early impact of the COVID-19 pandemic on adults with type 1 or type 2 diabetes: A national cohort study , 2020, Journal of Diabetes and its Complications.

[21]  Dima M. Qato,et al.  Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the US , 2020, JAMA network open.

[22]  Keith A. Marsolo,et al.  PCORnet® 2020: current state, accomplishments, and future directions , 2020, Journal of Clinical Epidemiology.

[23]  Kristy L Marynak,et al.  Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns — United States, June 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[24]  A. Purushotham,et al.  The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study , 2020, The Lancet Oncology.

[25]  A. Wright,et al.  The Invisible Epidemic: Neglected Chronic Disease Management During COVID-19 , 2020, Journal of General Internal Medicine.

[26]  I. Siempos,et al.  Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data , 2020, JCO global oncology.

[27]  S. Raoof,et al.  Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic , 2020, Journal of the American College of Radiology.

[28]  William R. Buckingham,et al.  Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. , 2018, The New England journal of medicine.

[29]  Virginia Moyer,et al.  The US Preventive Services Task Force , 2015, North Carolina Medical Journal.

[30]  Michael Klompas,et al.  Uses of electronic health records for public health surveillance to advance public health. , 2015, Annual review of public health.

[31]  Robert M Califf,et al.  The Patient-Centered Outcomes Research Network , 2014, North Carolina Medical Journal.